Crescita Financial Statements From 2010 to 2024
| CRRTF Stock | USD 0.45 0.00 0.00% |
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
Crescita |
Crescita Therapeutics Company Operating Margin Analysis
Crescita Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Crescita Therapeutics Operating Margin | 0.04 % |
Most of Crescita Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crescita Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Crescita Therapeutics has an Operating Margin of 0.0403%. This is 100.11% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 100.73% lower than that of the firm.
Crescita Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Crescita Therapeutics's current stock value. Our valuation model uses many indicators to compare Crescita Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Crescita Therapeutics competition to find correlations between indicators driving Crescita Therapeutics's intrinsic value. More Info.Crescita Therapeutics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.71 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Crescita Therapeutics is roughly 1.40 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Crescita Therapeutics' earnings, one of the primary drivers of an investment's value.About Crescita Therapeutics Financial Statements
Crescita Therapeutics stakeholders use historical fundamental indicators, such as Crescita Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Crescita Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Crescita Therapeutics' assets and liabilities are reflected in the revenues and expenses on Crescita Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Crescita Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada. Crescita Therapeutics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Crescita Pink Sheet
Crescita Therapeutics financial ratios help investors to determine whether Crescita Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.